The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Identifieur interne : 001A47 ( Main/Corpus ); précédent : 001A46; suivant : 001A48The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Auteurs : Wen Zhang ; Yan Zhao ; Fengchun Zhang ; Qian Wang ; Taisheng Li ; Zhengyin Liu ; Jinglan Wang ; Yan Qin ; Xuan Zhang ; Xiaowei Yan ; Xiaofeng Zeng ; Shuyang ZhangSource :
- Clinical immunology (Orlando, Fla.) [ 1521-7035 ] ; 2020.
English descriptors
- KwdEn :
- Anti-Inflammatory Agents (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Chloroquine (therapeutic use), Coronavirus Infections (drug therapy), Cytokines (immunology), Glucocorticoids (therapeutic use), Humans (MeSH), Hydroxychloroquine (therapeutic use), Inflammation (pathology), Interleukin-6 (antagonists & inhibitors), Janus Kinases (antagonists & inhibitors), Pandemics (MeSH), Pneumonia, Viral (drug therapy), SARS-CoV-2 (MeSH), Thrombosis (virology), Vasculitis (virology).
- MESH :
- chemical , antagonists & inhibitors : Interleukin-6, Janus Kinases.
- chemical , immunology : Cytokines.
- chemical , therapeutic use : Anti-Inflammatory Agents, Antibodies, Monoclonal, Humanized, Chloroquine, Glucocorticoids, Hydroxychloroquine.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- pathology : Inflammation.
- virology : Thrombosis, Vasculitis.
- Betacoronavirus, COVID-19, Humans, Pandemics, SARS-CoV-2.
Abstract
The pandemic outbreak of coronavirus disease 2019 (COVID-19) is rapidly spreading all over the world. Reports from China showed that about 20% of patients developed severe disease, resulting in a fatality of 4%. In the past two months, we clinical immunologists participated in multi-rounds of MDT (multidiscipline team) discussion on the anti-inflammation management of critical COVID-19 patients, with our colleagues dispatched from Chinese leading PUMC Hospital to Wuhan to admit and treat the most severe patients. Here, from the perspective of clinical immunologists, we will discuss the clinical and immunological characteristics of severe patients, and summarize the current evidence and share our experience in anti-inflammation treatment, including glucocorticoids, IL-6 antagonist, JAK inhibitors and choloroquine/hydrocholoroquine, of patients with severe COVID-19 that may have an impaired immune system.
DOI: 10.1016/j.clim.2020.108393
PubMed: 32222466
PubMed Central: PMC7102614
Links to Exploration step
pubmed:32222466Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.</title><author><name sortKey="Zhang, Wen" sort="Zhang, Wen" uniqKey="Zhang W" first="Wen" last="Zhang">Wen Zhang</name><affiliation><nlm:affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhao, Yan" sort="Zhao, Yan" uniqKey="Zhao Y" first="Yan" last="Zhao">Yan Zhao</name><affiliation><nlm:affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Fengchun" sort="Zhang, Fengchun" uniqKey="Zhang F" first="Fengchun" last="Zhang">Fengchun Zhang</name><affiliation><nlm:affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Qian" sort="Wang, Qian" uniqKey="Wang Q" first="Qian" last="Wang">Qian Wang</name><affiliation><nlm:affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China.</nlm:affiliation></affiliation></author><author><name sortKey="Li, Taisheng" sort="Li, Taisheng" uniqKey="Li T" first="Taisheng" last="Li">Taisheng Li</name><affiliation><nlm:affiliation>Clinical Immunology Centre, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China; Department of Infectious Disease, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China.</nlm:affiliation></affiliation></author><author><name sortKey="Liu, Zhengyin" sort="Liu, Zhengyin" uniqKey="Liu Z" first="Zhengyin" last="Liu">Zhengyin Liu</name><affiliation><nlm:affiliation>Department of Infectious Disease, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Jinglan" sort="Wang, Jinglan" uniqKey="Wang J" first="Jinglan" last="Wang">Jinglan Wang</name><affiliation><nlm:affiliation>Department of Respiratory Medicine, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China.</nlm:affiliation></affiliation></author><author><name sortKey="Qin, Yan" sort="Qin, Yan" uniqKey="Qin Y" first="Yan" last="Qin">Yan Qin</name><affiliation><nlm:affiliation>Department of Nephrology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Xuan" sort="Zhang, Xuan" uniqKey="Zhang X" first="Xuan" last="Zhang">Xuan Zhang</name><affiliation><nlm:affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China; Clinical Immunology Centre, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China.</nlm:affiliation></affiliation></author><author><name sortKey="Yan, Xiaowei" sort="Yan, Xiaowei" uniqKey="Yan X" first="Xiaowei" last="Yan">Xiaowei Yan</name><affiliation><nlm:affiliation>Department of Cardiology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China. Electronic address: xswy_pumc@163.com.</nlm:affiliation></affiliation></author><author><name sortKey="Zeng, Xiaofeng" sort="Zeng, Xiaofeng" uniqKey="Zeng X" first="Xiaofeng" last="Zeng">Xiaofeng Zeng</name><affiliation><nlm:affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China. Electronic address: xiaofeng.zeng@cstar.org.cn.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Shuyang" sort="Zhang, Shuyang" uniqKey="Zhang S" first="Shuyang" last="Zhang">Shuyang Zhang</name><affiliation><nlm:affiliation>Department of Cardiology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China. Electronic address: zhangshuyang2018@126.com.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32222466</idno><idno type="pmid">32222466</idno><idno type="doi">10.1016/j.clim.2020.108393</idno><idno type="pmc">PMC7102614</idno><idno type="wicri:Area/Main/Corpus">001A47</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001A47</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.</title><author><name sortKey="Zhang, Wen" sort="Zhang, Wen" uniqKey="Zhang W" first="Wen" last="Zhang">Wen Zhang</name><affiliation><nlm:affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhao, Yan" sort="Zhao, Yan" uniqKey="Zhao Y" first="Yan" last="Zhao">Yan Zhao</name><affiliation><nlm:affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Fengchun" sort="Zhang, Fengchun" uniqKey="Zhang F" first="Fengchun" last="Zhang">Fengchun Zhang</name><affiliation><nlm:affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Qian" sort="Wang, Qian" uniqKey="Wang Q" first="Qian" last="Wang">Qian Wang</name><affiliation><nlm:affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China.</nlm:affiliation></affiliation></author><author><name sortKey="Li, Taisheng" sort="Li, Taisheng" uniqKey="Li T" first="Taisheng" last="Li">Taisheng Li</name><affiliation><nlm:affiliation>Clinical Immunology Centre, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China; Department of Infectious Disease, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China.</nlm:affiliation></affiliation></author><author><name sortKey="Liu, Zhengyin" sort="Liu, Zhengyin" uniqKey="Liu Z" first="Zhengyin" last="Liu">Zhengyin Liu</name><affiliation><nlm:affiliation>Department of Infectious Disease, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Jinglan" sort="Wang, Jinglan" uniqKey="Wang J" first="Jinglan" last="Wang">Jinglan Wang</name><affiliation><nlm:affiliation>Department of Respiratory Medicine, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China.</nlm:affiliation></affiliation></author><author><name sortKey="Qin, Yan" sort="Qin, Yan" uniqKey="Qin Y" first="Yan" last="Qin">Yan Qin</name><affiliation><nlm:affiliation>Department of Nephrology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Xuan" sort="Zhang, Xuan" uniqKey="Zhang X" first="Xuan" last="Zhang">Xuan Zhang</name><affiliation><nlm:affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China; Clinical Immunology Centre, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China.</nlm:affiliation></affiliation></author><author><name sortKey="Yan, Xiaowei" sort="Yan, Xiaowei" uniqKey="Yan X" first="Xiaowei" last="Yan">Xiaowei Yan</name><affiliation><nlm:affiliation>Department of Cardiology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China. Electronic address: xswy_pumc@163.com.</nlm:affiliation></affiliation></author><author><name sortKey="Zeng, Xiaofeng" sort="Zeng, Xiaofeng" uniqKey="Zeng X" first="Xiaofeng" last="Zeng">Xiaofeng Zeng</name><affiliation><nlm:affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China. Electronic address: xiaofeng.zeng@cstar.org.cn.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Shuyang" sort="Zhang, Shuyang" uniqKey="Zhang S" first="Shuyang" last="Zhang">Shuyang Zhang</name><affiliation><nlm:affiliation>Department of Cardiology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China. Electronic address: zhangshuyang2018@126.com.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Clinical immunology (Orlando, Fla.)</title><idno type="eISSN">1521-7035</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Inflammatory Agents (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Chloroquine (therapeutic use)</term><term>Coronavirus Infections (drug therapy)</term><term>Cytokines (immunology)</term><term>Glucocorticoids (therapeutic use)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Inflammation (pathology)</term><term>Interleukin-6 (antagonists & inhibitors)</term><term>Janus Kinases (antagonists & inhibitors)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>SARS-CoV-2 (MeSH)</term><term>Thrombosis (virology)</term><term>Vasculitis (virology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Interleukin-6</term><term>Janus Kinases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Cytokines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Antibodies, Monoclonal, Humanized</term><term>Chloroquine</term><term>Glucocorticoids</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Inflammation</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Thrombosis</term><term>Vasculitis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>COVID-19</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The pandemic outbreak of coronavirus disease 2019 (COVID-19) is rapidly spreading all over the world. Reports from China showed that about 20% of patients developed severe disease, resulting in a fatality of 4%. In the past two months, we clinical immunologists participated in multi-rounds of MDT (multidiscipline team) discussion on the anti-inflammation management of critical COVID-19 patients, with our colleagues dispatched from Chinese leading PUMC Hospital to Wuhan to admit and treat the most severe patients. Here, from the perspective of clinical immunologists, we will discuss the clinical and immunological characteristics of severe patients, and summarize the current evidence and share our experience in anti-inflammation treatment, including glucocorticoids, IL-6 antagonist, JAK inhibitors and choloroquine/hydrocholoroquine, of patients with severe COVID-19 that may have an impaired immune system.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32222466</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-7035</ISSN><JournalIssue CitedMedium="Internet"><Volume>214</Volume><PubDate><Year>2020</Year><Month>05</Month></PubDate></JournalIssue><Title>Clinical immunology (Orlando, Fla.)</Title><ISOAbbreviation>Clin Immunol</ISOAbbreviation></Journal><ArticleTitle>The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.</ArticleTitle><Pagination><MedlinePgn>108393</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1521-6616(20)30198-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clim.2020.108393</ELocationID><Abstract><AbstractText>The pandemic outbreak of coronavirus disease 2019 (COVID-19) is rapidly spreading all over the world. Reports from China showed that about 20% of patients developed severe disease, resulting in a fatality of 4%. In the past two months, we clinical immunologists participated in multi-rounds of MDT (multidiscipline team) discussion on the anti-inflammation management of critical COVID-19 patients, with our colleagues dispatched from Chinese leading PUMC Hospital to Wuhan to admit and treat the most severe patients. Here, from the perspective of clinical immunologists, we will discuss the clinical and immunological characteristics of severe patients, and summarize the current evidence and share our experience in anti-inflammation treatment, including glucocorticoids, IL-6 antagonist, JAK inhibitors and choloroquine/hydrocholoroquine, of patients with severe COVID-19 that may have an impaired immune system.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Fengchun</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Taisheng</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clinical Immunology Centre, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China; Department of Infectious Disease, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhengyin</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jinglan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China; Clinical Immunology Centre, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Xiaowei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China. Electronic address: xswy_pumc@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China. Electronic address: xiaofeng.zeng@cstar.org.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shuyang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China. Electronic address: zhangshuyang2018@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Immunol</MedlineTA><NlmUniqueID>100883537</NlmUniqueID><ISSNLinking>1521-6616</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="D053612">Janus Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Clin Immunol. 2020 Jul;216:108442</RefSource><PMID Version="1">32335290</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053612" MajorTopicYN="N">Janus Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="N">Thrombosis</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014657" MajorTopicYN="N">Vasculitis</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Anti-inflammation treatment</Keyword><Keyword MajorTopicYN="Y">Coronavirus disease 2019 (COVID-19)</Keyword><Keyword MajorTopicYN="Y">Cytokine storm</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32222466</ArticleId><ArticleId IdType="pii">S1521-6616(20)30198-4</ArticleId><ArticleId IdType="doi">10.1016/j.clim.2020.108393</ArticleId><ArticleId IdType="pmc">PMC7102614</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Respir Crit Care Med. 2003 Dec 15;168(12):1449-56</Citation><ArticleIdList><ArticleId IdType="pubmed">12947028</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunother Cancer. 2018 Jun 15;6(1):56</Citation><ArticleIdList><ArticleId IdType="pubmed">29907163</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 2020 May;46(5):846-848</Citation><ArticleIdList><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331</Citation><ArticleIdList><ArticleId IdType="pubmed">32171193</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):473-475</Citation><ArticleIdList><ArticleId IdType="pubmed">32043983</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 2017 Mar;43(3):304-377</Citation><ArticleIdList><ArticleId IdType="pubmed">28101605</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Biochem Funct. 2016 Jun;34(4):191-6</Citation><ArticleIdList><ArticleId IdType="pubmed">27001679</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS Res Ther. 2017 Sep 12;14(1):46</Citation><ArticleIdList><ArticleId IdType="pubmed">28893304</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2006 Jun;129(6):1441-52</Citation><ArticleIdList><ArticleId IdType="pubmed">16778260</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):420-422</Citation><ArticleIdList><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Discov Ther. 2020;14(1):58-60</Citation><ArticleIdList><ArticleId IdType="pubmed">32147628</ArticleId></ArticleIdList></Reference><Reference><Citation>J Interferon Cytokine Res. 2015 Mar;35(3):143-56</Citation><ArticleIdList><ArticleId IdType="pubmed">25321315</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):411-417</Citation><ArticleIdList><ArticleId IdType="pubmed">32172546</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2005 Aug;51(2):98-102</Citation><ArticleIdList><ArticleId IdType="pubmed">16038758</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Mar 17;323(11):1061-1069</Citation><ArticleIdList><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1990 Feb;174(2):450-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2154882</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Antivir Chem Chemother. 2006;17(5):275-84</Citation><ArticleIdList><ArticleId IdType="pubmed">17176632</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhonghua Shao Shang Za Zhi. 2020 Jun 20;36(6):471-475</Citation><ArticleIdList><ArticleId IdType="pubmed">32114747</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Chin Med. 2020;48(3):737-762</Citation><ArticleIdList><ArticleId IdType="pubmed">32164424</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation><ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):e30-e31</Citation><ArticleIdList><ArticleId IdType="pubmed">32032529</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):762-768</Citation><ArticleIdList><ArticleId IdType="pubmed">32161940</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Omega. 2018 Dec 31;3(12):18132-18141</Citation><ArticleIdList><ArticleId IdType="pubmed">30613818</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Jun;92(6):540-545</Citation><ArticleIdList><ArticleId IdType="pubmed">32108352</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Immunopathol. 2017 Jul;39(5):529-539</Citation><ArticleIdList><ArticleId IdType="pubmed">28466096</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Immunopathol. 2017 Jul;39(5):517-528</Citation><ArticleIdList><ArticleId IdType="pubmed">28555385</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation><ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Jun;92(6):548-551</Citation><ArticleIdList><ArticleId IdType="pubmed">32096567</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Intern Med. 2020 Jul 1;180(7):934-943</Citation><ArticleIdList><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Immunopathol. 2017 Jul;39(5):541-550</Citation><ArticleIdList><ArticleId IdType="pubmed">28555383</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2007 Jan;54(1):28-39</Citation><ArticleIdList><ArticleId IdType="pubmed">16542729</ArticleId></ArticleIdList></Reference><Reference><Citation>J Heart Lung Transplant. 2020 May;39(5):405-407</Citation><ArticleIdList><ArticleId IdType="pubmed">32362390</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):507-513</Citation><ArticleIdList><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001A47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32222466
|texte= The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32222466" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |